JY
HEPA

Jeff Yass’s Hepion Pharmaceuticals HEPA Stock Holding History

Jeff Yass’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12
Closed -$6K – 12919
2022
Q3 		$6K Sell
12
-3
-20% -$1.83K ﹤0.01% 12854
2022
Q2 		$9K Buy
15
+2
+15% +$1.67K ﹤0.01% 12529
2022
Q1 		$17K Sell
13
-28
-68% -$30.9K ﹤0.01% 12663
2021
Q4 		$47K Sell
41
-155
-79% -$212K ﹤0.01% 12581
2021
Q3 		$299K Sell
196
-261
-57% -$418K ﹤0.01% 10606
2021
Q2 		$905K Sell
457
-96
-17% -$176K ﹤0.01% 8042
2021
Q1 		$1.02M Buy
553
+423
+325% +$927K ﹤0.01% 7696
2020
Q4 		$285K Buy
+130
New +$337K ﹤0.01% 9375

Other funds holding HEPA

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's HEPA Position: Q1 2025 in Review

Jeff Yass sold out of Hepion Pharmaceuticals (HEPA) in Q1 2025, closing a stake of 521 shares — an estimated $12.2K sold.

Jeff Yass first reported a position in HEPA in Q2 2019 and held it in 18 quarters. The position peaked at $651K in Q1 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q1 2025.

  • Jeff Yass reported no remaining Hepion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Jeff Yass sold 521 Hepion Pharmaceuticals shares in Q1 2025, an estimated $12.2K.
  • Jeff Yass first reported a position in Hepion Pharmaceuticals in Q2 2019 and held it in 18 quarters.
  • Jeff Yass's Hepion Pharmaceuticals position peaked at $651K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.